Subscribe

Rylaze FDA Approved as Part of a Treatment Regimen for Pediatric Leukemia and Lymphoma

August 2021 Vol 14, Special Issue: Payers' Perspectives in Oncology - FDA Approvals, Leukemia, Lymphoma, Conference Highlights ASCO

On June 30, 2021, the FDA accelerated the approval of asparaginase erwinia chrysanthemi (recombinant)-rywn (Rylaze; Jazz Pharmaceuticals), an asparagine-specific enzyme, as a component of a multidrug chemotherapy regimen for the treatment of acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma in patients aged ≥1 months with hypersensitivity to Escherichia coli–derived asparaginase.

The FDA granted erwinia chrysanthemi an orphan drug designation for this indication. Erwinia chrysanthemi will address the shortages of Erwinia asparaginase (Erwinaze). Rylaze “has the same molecular makeup as Erwinaze. But it’s manufactured differently, and in a more efficient way, so having the option to substitute Rylaze should reduce the likelihood of treatment shortages for these patients in the future,” said Malcolm A. Smith, MD, PhD, Associate Branch Chief for Pediatric Oncology, NCI’s Cancer Therapy Evaluation Program.

Erwinia chrysanthemi can be used as a substitute to Erwinia asparaginase in people with an immune reaction to pegaspargase. These ongoing shortages have been “incredibly stressful to patients and their parents,” said Sumit Gupta, MD, PhD, University of Toronto, and Pediatric Oncologist, Hospital for Sick Children, Toronto, Canada.

The FDA approved erwinia chrysanthemi based on results of an open-label, multicohort, multicenter clinical trial of 102 patients (median age, 10 years; range, 1-24 years) with ALL or lymphoblastic lymphoma and hypersensitivity to asparaginase caused by E coli infection, as part of a multidrug chemotherapy regimen.

The primary end point was achievement and maintenance of nadir serum asparaginase activity (NSAA) >0.1 U/mL. The results of modeling and simulations showed that for a dosage of 25 mg/m2 administered every 48 hours, the proportion of patients maintaining NSAA ≥0.1 U/mL at 48 hours after a dose of erwinia chrysanthemi was 93.6% (95% confidence interval, 92.6%-94.6%).

The most common (>20%) adverse reactions were abnormal liver test, nausea, musculoskeletal pain, fatigue, infection, headache, pyrexia, drug hypersensitivity, febrile neutropenia, decreased appetite, stomatitis, bleeding, and hyperglycemia.

Related Items
Tabrecta (Capmatinib) First FDA-Approved Drug for Metastatic NSCLC with MET Exon 14 Skipping Mutation
Loretta Fala
August 2021 Vol 14, Special Issue: Payers' Perspectives in Oncology published on October 27, 2021 in Conference Highlights ASCO, Drug Updates
Ukoniq (Umbralisib) FDA Approved for Adults with Relapsed or Refractory Marginal-Zone Lymphoma or Follicular Lymphoman
Loretta Fala
August 2021 Vol 14, Special Issue: Payers' Perspectives in Oncology published on October 27, 2021 in Conference Highlights ASCO
Jemperli (Dostarlimab) First Immunotherapy Approved for Recurrent or Advanced Mismatch Repair-Deficient Endometrial Cancer
Loretta Fala
August 2021 Vol 14, Special Issue: Payers' Perspectives in Oncology published on October 27, 2021 in Conference Highlights ASCO
Abecma (Idecabtagene Vicleucel) First-in-Class BCMA-Directed CAR T-Cell Therapy Approved for Relapsed or Refractory Multiple Myeloma
Loretta Fala
August 2021 Vol 14, Special Issue: Payers' Perspectives in Oncology published on October 25, 2021 in Conference Highlights ASCO
Opdivo First FDA-Approved Immunotherapy for First-Line Treatment of Advanced Gastric Cancer
Web Exclusives published on August 9, 2021 in FDA Approvals
Last modified: August 30, 2021
Copyright © Engage Healthcare Communications, LLC. All rights reserved.